Por favor, tente outra busca
Código | Bolsa | Moeda | ||
---|---|---|---|---|
AMGN | NASDAQ | USD | Tempo Real | |
AMGN | México | MXN | Atrasada | |
AMGN | BIVA | MXN | Atrasada | |
AAMGN | Milão | EUR | Tempo Real | |
AMGN | TradeGate | EUR | Atrasada | |
AMGN | Xetra | EUR | Atrasada | |
AMGN | Frankfurt | EUR | Atrasada | |
AMGNm | Buenos Aires | ARS | Atrasada | |
AMGN34 | B3 | BRL | Atrasada | |
AMGN | Viena | EUR | Tempo Real | |
AMGN | Lima | USD | Atrasada |
descobre, desenvolve, fabrica e fornece terapêutica humana em todo o mundo. Os principais produtos da empresa incluem Enbrel para tratar psoríase em placas, artrite reumatoide e artrite psoriásica; Otezla para o tratamento de pacientes adultos com psoríase em placas, artrite psoriásica e úlceras orais associadas à doença de Behçet; Prolia para tratar mulheres na pós-menopausa com osteoporose; XGEVA para prevenção de eventos relacionados ao esqueleto; Repatha, que reduz os riscos de infarto do miocárdio, acidente vascular cerebral e revascularização coronariana; Nplate para o tratamento de pacientes com trombocitopenia imune; KYPROLIS para tratar doentes com mieloma múltiplo recidivante ou refratário; Aranesp para tratar um número menor do que o normal de glóbulos vermelhos e anemia; EVENITY para o tratamento da osteoporose na pós-menopausa para homens e mulheres; Vectibix para tratar doentes com cancro colorretal metastático do tipo selvagem do SRA; BLINCYTO para o tratamento de pacientes com leucemia linfoblástica aguda; TEPEZZA para tratar doenças oculares da tireoide; e KRYSTEXXA para o tratamento da gota crônica refratária. Também comercializa outros produtos, incluindo Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA e PROCYSBI. A empresa atende prestadores de serviços de saúde, incluindo médicos ou suas clínicas, centros de diálise, hospitais e farmácias. Distribui seus produtos por meio de distribuidores atacadistas farmacêuticos, bem como canais diretos ao consumidor. A empresa tem acordos de colaboração com a AstraZeneca plc para o desenvolvimento e comercialização de TEZSPIRE; Novartis Pharma AG para desenvolver e comercializar Aimovig; UCB para o desenvolvimento e comercialização de EVENITY; Kyowa Kirin Co., Ltd. para desenvolvimento e comercialização de rocatinlimab; e BeiGene, Ltd. para expansão e desenvolvimento de produtos oncológicos. foi constituída em 1980 e está sediada em Thousand Oaks, Califórnia.
Nome | Idade | Desde | Título |
---|---|---|---|
Robert A. Bradway | 58 | 2007 | Chairman, CEO & President |
Tyler E. Jacks | 62 | 2012 | Independent Director |
David Baltimore | 85 | 1999 | Co-Chair of Scientific Advisory Board |
Charles M. Holley | 66 | 2017 | Independent Director |
Charles Elliott Sigal | 72 | - | Co-Chair of the Scientific Advisory Board |
Ellen J. Kullman | 68 | 2016 | Independent Director |
Robert A. Eckert | 70 | 2012 | Lead Independent Director |
Amy E. Miles | 57 | 2020 | Independent Director |
Wanda M. Austin | 70 | 2017 | Independent Director |
Greg C. Garland | 67 | 2013 | Independent Director |
Brian J. Druker | 68 | 2018 | Independent Director |
S. Omar Ishrak | 68 | 2021 | Independent Director |
Benoit Van den Eynde | - | - | Member of Scientific Advisory Board of Oncology |
David J. Anderson | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Diane J. Mathis | - | - | Member of Scientific Advisory Board of Inflammation |
Dean Sheppard | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Alexander Rudensky | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Alexander Marson | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Arlene Sharpe | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Ruslan Medzhitov | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Antoni Ribas | 57 | - | Member of Scientific Advisory Board of Oncology |
Peter Libby | 77 | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Robert S. Negrin | - | - | Member of Scientific Advisory Board of Oncology |
Daniel P. Kelly | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Daniel Joshua Drucker | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Frank P. McCormick | 74 | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Michael V. Drake | 73 | 2022 | Independent Director |
S. Gail Eckhardt | - | 2022 | Member of Scientific Advisory Board of Oncology |
Mary E. Klotman | - | 2024 | Director |
George Georgiou | 65 | 2023 | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Richard O. Hynes | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Emma Guttman-Yassky | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Meilan Han | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Marlene Rabinovitch | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
David Alan Kass | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Jonathan S. Weissman | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
E. Dale Abel | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Lillian L. Siu | - | 2022 | Member of Scientific Advisory Board of Oncology |
Maria T. Abreu | - | 2022 | Member of Scientific Advisory Board of Inflammation |
John Kuriyan | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Elizabeth McNally | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Jeffery D. Molkentin | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Siwen Hu-Lieskovan | - | - | Member of Scientific Advisory Board of Oncology |
Drew Mark Pardoll | - | - | Member of Scientific Advisory Board of Oncology |
Ronald M. Evans | 75 | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Dirk Jäger | - | - | Member of Scientific Advisory Board of Oncology |
Robert Tjian | 75 | - | Member of Scientific Advisory Board Member of Research Trends & Emerging Technologies |
Thomas Quertermous | 72 | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Fabrice Andre | - | - | Member of Scientific Advisory Board of Oncology |
Tem certeza de que deseja bloquear %USER_NAME%?
Ao confirmar o bloqueio, você e %USER_NAME% não poderão ver o que cada um de vocês posta no Investing.com.
%USER_NAME% foi adicionado com êxito à sua Lista de bloqueios
Já que acabou de desbloquear esta pessoa, você deve aguardar 48 horas antes de bloqueá-la novamente.
Diga-nos o que achou desse comentário
Obrigado!
Seu comentário foi enviado aos moderadores para revisão